• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢浆液性交界性肿瘤

Serous borderline tumours of the ovary.

作者信息

Kurman R J, Seidman J D, Shih I-M

机构信息

Department of Pathology, Washington Hospital Center, Washington, DC, USA.

出版信息

Histopathology. 2005 Sep;47(3):310-5. doi: 10.1111/j.1365-2559.2005.02186.x.

DOI:10.1111/j.1365-2559.2005.02186.x
PMID:16115232
Abstract

Serous borderline tumours of the ovaryIn this Expert Opinion we have invited articles from two leading groups, to discuss serous borderline tumours (serous tumours of low malignant potential) of the ovary from their own perspectives. Controversy remains over heterogeneity within this group of tumours and their relationship to ovarian cancer. Our authors discuss the histopathological classification of these tumours in relation to morphological appearances, molecular and clinical data. The significance of a micropapillary pattern is discussed, and issues related to extra-ovarian implants.

摘要

卵巢浆液性交界性肿瘤

在本专家意见中,我们邀请了两个顶尖团队撰写文章,从他们各自的角度探讨卵巢浆液性交界性肿瘤(低度恶性潜能浆液性肿瘤)。关于这类肿瘤内部的异质性及其与卵巢癌的关系仍存在争议。我们的作者结合形态学表现、分子和临床数据讨论了这些肿瘤的组织病理学分类。探讨了微乳头模式的意义以及与卵巢外种植相关的问题。

相似文献

1
Serous borderline tumours of the ovary.卵巢浆液性交界性肿瘤
Histopathology. 2005 Sep;47(3):310-5. doi: 10.1111/j.1365-2559.2005.02186.x.
2
A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.卵巢肿瘤发生的多步骤模型:KRAS和BRAF基因中突变分析的价值
J Pathol. 2004 Jun;203(2):617-9. doi: 10.1002/path.1563.
3
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.在卵巢肿瘤中,BRAF突变(而非KRAS突变)仅限于低级别浆液性肿瘤。
J Pathol. 2004 Mar;202(3):336-40. doi: 10.1002/path.1521.
4
The pathology of and controversial aspects of ovarian borderline tumours.卵巢交界性肿瘤的病理与争议性问题。
Curr Opin Oncol. 2010 Sep;22(5):462-72. doi: 10.1097/CCO.0b013e32833b0dc1.
5
KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.卵巢肿瘤中的KRAS和BRAF突变:对浸润性癌、交界性肿瘤和卵巢外种植体的综合研究
Gynecol Oncol. 2006 Dec;103(3):883-7. doi: 10.1016/j.ygyno.2006.05.029. Epub 2006 Jun 30.
6
Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.卵巢交界性肿瘤的分子发病机制:新见解与旧挑战
Clin Cancer Res. 2005 Oct 15;11(20):7273-9. doi: 10.1158/1078-0432.CCR-05-0755.
7
Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.在交界性和低级别卵巢癌中测定BRAF V600E(VE1)蛋白表达及第600密码子处BRAF基因突变状态。
Tumour Biol. 2017 May;39(5):1010428317706230. doi: 10.1177/1010428317706230.
8
Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.卵巢交界性上皮性肿瘤——31例回顾性分析
Indian J Cancer. 1999 Mar;36(1):18-31.
9
K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Gynecol Oncol. 2001 Feb;80(2):201-6. doi: 10.1006/gyno.2000.6066.
10
[Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].[评估腹膜扩展在浆液性卵巢交界性肿瘤诊断和管理中的作用]
Rev Med Chir Soc Med Nat Iasi. 2006 Jul-Sep;110(3):679-86.

引用本文的文献

1
Fertility-sparing surgery versus radical surgery for micropapillary serous borderline ovarian tumours: a systematic review protocol.保留生育功能手术与激进手术治疗微乳头状浆液性交界性卵巢肿瘤:系统评价方案。
BMJ Open. 2024 Nov 12;14(11):e077503. doi: 10.1136/bmjopen-2023-077503.
2
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.浆液性交界性肿瘤细分为非典型增生性肿瘤和非浸润性低级别癌的长期行为:一项基于人群的942例临床病理研究
Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.
3
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
原发性透明细胞卵巢癌中 KRAS、NRAS 和 BRAF 的突变状态。
Virchows Arch. 2014 Aug;465(2):193-8. doi: 10.1007/s00428-014-1599-1. Epub 2014 Jun 3.
4
KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.KRAS、BRAF基因分型揭示了卵巢交界性肿瘤及相关种植灶的基因异质性。
BMC Cancer. 2013 Oct 18;13:483. doi: 10.1186/1471-2407-13-483.
5
Whole exome sequence analysis of serous borderline tumors of the ovary.卵巢浆液性交界性肿瘤的全外显子组序列分析。
Gynecol Oncol. 2013 Sep;130(3):560-4. doi: 10.1016/j.ygyno.2013.06.007. Epub 2013 Jun 14.
6
Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma.正常输卵管伞端的生物标志物表达:高级别与低级别浆液性卵巢癌的比较。
Oncol Lett. 2012 Nov;4(5):1008-1012. doi: 10.3892/ol.2012.877. Epub 2012 Aug 23.
7
Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.Ⅱ期和Ⅲ期浆液性交界性卵巢肿瘤患者中微乳头模式的预后和预后因素。
Oncologist. 2011;16(2):189-96. doi: 10.1634/theoncologist.2009-0139. Epub 2011 Jan 27.
8
Risk factors for recurrence of ovarian borderline tumors.卵巢交界性肿瘤复发的危险因素。
Gynecol Oncol. 2011 Mar;120(3):480-4. doi: 10.1016/j.ygyno.2010.11.016. Epub 2010 Dec 10.
9
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.Ⅱ期-Ⅳ期浆液性卵巢交界性肿瘤的复发模式及辅助化疗的作用。
Gynecol Oncol. 2010 Nov;119(2):270-3. doi: 10.1016/j.ygyno.2010.07.019. Epub 2010 Aug 16.
10
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.良性、低恶性潜能及低级别浆液性上皮性卵巢肿瘤的免疫组织化学分析
BMC Cancer. 2008 Nov 26;8:346. doi: 10.1186/1471-2407-8-346.